Venrock Group Reports 2,047,620 Shares of Pharvaris (3.8%)
Rhea-AI Filing Summary
Pharvaris N.V. Schedule 13G/A discloses that a group of Venrock-related entities and two individuals beneficially own an aggregate of 2,047,620 ordinary shares of Pharvaris, representing 3.8% of the class as of June 30, 2025. The filing breaks this down as 380,109 shares held by Venrock Healthcare Capital Partners III, L.P., 38,028 by VHCP Co-Investment Holdings III, LLC, and 1,629,483 by Venrock Healthcare Capital Partners EG, L.P. The 3.8% percentage is calculated using 54,493,142 ordinary shares outstanding per the issuer's prospectus supplement dated July 22, 2025 (filed July 24, 2025). All entity filers are organized in Delaware; Nimish Shah and Bong Koh are U.S. citizens. The filing is signed on behalf of the reporting persons by Sherman G. Souther (authorized signatory) on August 14, 2025, and includes a certification that the securities were not acquired to influence control of the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR: Venrock group holds 2,047,620 shares (3.8%), a non-control passive stake reported for transparency.
The Schedule 13G/A shows an aggregate 3.8% beneficial ownership by Venrock-affiliated funds and named individuals as of June 30, 2025. The position is below the 5% threshold and the filing explicitly states the holdings were not acquired to influence control. The breakdown across funds identifies where economic exposure resides: VHCP EG holds the majority of the position. For investors, this is a disclosure of a modest institutional stake rather than a control or activist signal.
TL;DR: This is a routine joint 13G disclosure by a group asserting passive intent; governance impact appears limited.
The filing identifies a group of Venrock entities and two individuals filing jointly, with shared voting and dispositive power over 2,047,620 shares. The document includes standard powers of attorney and a joint filing agreement referenced by exhibits. Because the stake is under 5% and accompanied by a non-control certification, it signals disclosure compliance without immediate governance implications.
FAQ
What percentage of Pharvaris does the reported stake represent?
Does the filing indicate an intent to influence control of Pharvaris?
Who signed the Schedule 13G/A on behalf of the reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.